Lupin settles patent dispute with Astellas for $90 million
The product is indicated for treating an overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency
The product is indicated for treating an overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency
What's Your Reaction?
DDP Editor
Admin managing news updates, RSS feed curation, and PR content publishing. Focused on timely, accurate, and impactful information delivery.
